• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
73,319.55 0.00
( 0.00%)
Global Indices
Nasdaq
46,525.67 -61.07
(-0.13%)
Dow Jones
6,603.69 7.37
(0.11%)
Hang Seng
53,162.49 699.22
(1.33%)
Nikkei 225
10,436.29 71.50
(0.69%)
Forex
USD-INR
93.02 -0.15
(-0.16%)
EUR-INR
107.32 -0.65
(-0.60%)
GBP-INR
123.03 -0.78
(-0.63%)
JPY-INR
0.58 0.00
(-0.67%)

EQUITY - MARKET SCREENER

Aarti Drugs Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs
BSE Code
ISIN Demat
Book Value()
524348
INE767A01016
147.0110661
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
AARTIDRUGS
17.3
3213.16
EPS(TTM)
Face Value()
Div & Yield %
20.35
10
0.28
 

shah metacorp ltd
Ashok Leyland’s total sales climb 24% YoY to 22,157 units in Feb’26
Mar 02,2026
Total Medium & Heavy Commercial Vehicles (M&HCV) sales jumped 28% YoY to 14,755 units in February 26, while light commercial vehicle (LCV) sales climbed 15% YoY to 7,402 units in February 2026.

In the domestic market, total vehicle sales increased 28% to 20,314 units in February 2026 compared with 15,879 units in February 2025. Total Medium & Heavy commercial vehicles sales jumped 31% YoY to 13,264 units in February 2026.

Ashok Leyland is involved in the manufacture and sale of a broad range of commercial vehicles and also makes engines for industrial and marine applications, as well as forgings and castings.

The company’s consolidated net profit increased 6.8% YoY to Rs 813.49 crore in Q3 FY26 compared with Rs 761.92 crore in Q3 FY25. Net sales jumped 23.6% to Rs 14,761.95 crore in the quarter ended 31st December 2025.

The scrip shed 0.17% to Rs 210.75 on the BSE.